Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,202 across all filing types
Latest filing 2023-04-21 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
关于使用部分暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Lingkang Pharmaceutical Group Co., Ltd. regarding the use of temporarily idle raised funds for cash management. It details the board meeting resolutions, investment scope, risk control measures, and opinions from independent directors, supervisors, and the sponsoring institution. The document is relatively short (2846 characters) and serves as a formal disclosure of a corporate financing-related decision rather than a full financial report or audit. It does not contain financial statements or detailed financial analysis but rather informs shareholders and the market about the company's plan to manage idle raised funds. This fits the definition of a Capital/Financing Update (CAP) as it relates to the use and management of raised capital funds.
2023-04-21 Chinese
第四届董事会第七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the seventh meeting of the fourth board of directors of Lingkang Pharmaceutical Group Co., Ltd. It includes approvals of various reports such as the 2022 General Manager Work Report, 2022 Board Work Report, 2022 Annual Report, 2022 Financial Final Accounts Report, profit distribution plan, and other governance and operational matters. The document also mentions that these reports and proposals will be submitted to the 2022 Annual General Meeting for approval. The content is focused on board meeting decisions and governance matters rather than the full annual report itself. The document length is 3905 characters, which is relatively short and mainly summarizes board resolutions rather than providing full financial statements or detailed analysis. Therefore, it is best classified as Board/Management Information (MANG) because it announces board meeting resolutions and management decisions rather than the full annual report or financial statements.
2023-04-21 Chinese
关于变更公司注册地址、经营范围及修改《公司章程》的公告
Governance Information Classification · 95% confidence The document is an official announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding changes to the company's business scope, registered address, and amendments to the company's articles of association. It includes details about the board meeting approving these changes and specific modifications to the articles. There is no financial data, no mention of annual or interim reports, earnings, or audit information. The document is a formal announcement about corporate governance matters, specifically changes to company registration and articles of association, which fits the category of Governance Information (CGR). The document length is short (1214 characters), and it is not a report publication announcement or a certification. Therefore, the best classification is Governance Information (CGR).
2023-04-21 Chinese
中信证券股份有限公司关于灵康药业集团股份有限公司2022年度募集资金存放与使用情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from CITIC Securities regarding the 2022 annual verification of the deposit and use of raised funds by Lingkang Pharmaceutical Group Co., Ltd. It includes extensive financial data on the raised funds from the 2015 IPO and the 2020 convertible bonds issuance, their management, usage, and compliance with regulatory requirements. The document also contains auditor's verification opinions and detailed tables of fund usage and balances. The content focuses on the management and use of raised capital, consistent with regulatory guidelines and audit verification. This matches the definition of an Audit Report / Information (AR), as it is a standalone audit-related report on the use of raised funds, not a full annual report or earnings release. The document length (over 11,000 characters) and detailed financial data confirm it is a substantive report, not merely an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2022
2023-04-21 Chinese
关于公司及全资子公司向银行申请2023年度综合授信额度及提供相应担保事项的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's and its subsidiaries' application for a comprehensive credit line and provision of guarantees to banks for the year 2023. It details the credit amounts, guarantee amounts, authorization for legal representatives to handle related procedures, and financial data of the subsidiaries. There is no indication that this is a full financial report, audit, or earnings release. The content focuses on financing activities and credit facilities. The document length is 2615 characters, which is relatively short and typical for an announcement rather than a full report. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2023-04-21 Chinese
公司董事会审计委员会2022年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as a report on the 2022 annual performance of the company's Board Audit Committee. It details the committee's activities, meetings, supervision of external auditors, internal audit guidance, and evaluation of internal controls for the year 2022. It references compliance with governance codes and regulatory requirements but does not contain full financial statements or detailed audit opinions themselves. The document is a summary report of the audit committee's work rather than a standalone audit report or full annual report. Given the focus on audit committee activities and oversight, this fits best under the category of Audit Report / Information (AR), which includes reports on audit committee activities and audit supervision, excluding full annual reports. FY 2022
2023-04-21 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.